B.A., Biology, University of California, Santa Cruz
Ph.D., Biochemistry, University of California, Davis
San Mateo, CA 94403
USA
Fax:
Mobile Number:
Email address:
Website URL:
Pharmaceutical product development
Process development
Manufacturing
CMC
Dr. Chamow has more than 20 years of experience in biopharmaceutical product development. He is currently a principal consultant helping to design and implement CMC strategy for companies developing biotechnology products. During his career, he has contributed to the development of three marketed products (Avastin, Natrecor, Vectibix). Previously, he served as Senior Vice President, CMC, at Intradigm Corporation, a
private biopharmaceutical company focused on developing RNAi therapeutics (acquired by Silence Therapeutics). Prior to Intradigm, Dr. Chamow was Vice President, Process Sciences, at Genitope Corporation and at Abgenix, Inc., (acquired by Amgen) where he built the company’s process sciences department and helped to lead the design and construction of Abgenix’ award-winning production facility in Fremont, CA. Before Abgenix, he served as Director of Biopharmaceutical Development at Scios, Inc. (acquired by J&J), and as a scientist and senior scientist in process development at Genentech, Inc. (acquired by Roche). Dr. Chamow was educated at the University of California (UC Santa Cruz, B.A. in biology; UC Davis, Ph.D. in biochemistry), and completed postdoctoral training at the National Institutes of Health. Dr. Chamow is author or co-author of more than 45 scientific publications and patents and co-editor of a 1999 book entitled Antibody Fusion Proteins.
